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Abstract 39 
In the present paper the development and application of a novel somatostatin 40 
radioimmunoassay are described. 125I-labeling of Tyr(0)-somatostain-14 (tyrosin(0)-41 
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somatostain-14) was performed by the iodogen-method and the mono-iodinated peptide 42 
was separated by reversed-phase HPLC. As a practical application of the novel RIA, the 43 
present work measured the somatostatin concentration parallel with the determination of 44 
thrittene content in different rat brain areas. The highest somatostatin concentrations were 45 
detected in the cerebellum. The thrittene immunoreactivity in the same brain parts 46 
showed a similar tendency. In the presesnt study concluded that thrittene is not created 47 
via a specific biosynthetical route, but from the pre-prosomatostatin. 48 
 49 
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 53 
Introduction 54 
  During our research we were investigating the distribution of two peptide 55 
hormones from the same peptide family, namely the somatostatin and the thrittene, in the 56 
rat central nervous system (CNS) with radioimmunoassay (RIA).  57 
The somatostatin was discovered in 1973 by Brazeau at al. as a peptide which potently 58 
inhibited growth hormone release from the anterior pituitary [1]. Originally it was 59 
isolated from the hypothalamus, but thereafter was evinced in the CNS, gastrointestinal 60 
tract (GIT) and the pancreas with immunohistochemistry and RIA [2, 3]. Somatostatin 61 
has two biologically active form, the 28 and the 14 amino acids containing cyclic 62 
polypeptides (Table 1.), which are produced in the CNS, primarily in the hypothalamic 63 
neurons, furthermore in the D cells of the GIT and the pancreas [4]. From the coding 64 
gene, 116 amino acids containing, preprosomatostatin is synthesized. This primary 65 
precursor is cleaved to form pro-somatostatin, a further precursor consists of 92 amino 66 
acids [5]. This molecule undergoes proteolytic processing at the COOH terminus as well 67 
as at the HN2 terminus. This C-terminal cleavage leads to the biologically active 68 
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somatostatin-28 form, from which another enzymatic cleavage results in the 69 
somatostatin-14 [6-8]. From its discovery as an inhibitor, somatostatin is known to be a 70 
universal inhibitory substance with multiple actions: it may act as a hormone via the 71 
circulation, as a paracrine effector via local regulatory mechanisms, or as a 72 
neurotransmitter via synaptic junctions [9].  73 
Thrittene belongs also to the family of related peptides containing somatostatin and 74 
cortistatin (Table 1.). It was identified by Ensinck at al. in 2002 and the peptide was 75 
purified from monkey ileum. Its amino acid sequence, molecular mass and 76 
chromatographic characteristics conformed to those of somatostatin-28 (1-13), a peptide 77 
not describe heretofore. The peptide was detected in the GI tract of mammalians by 78 
immunohistochemistry, and then developed a subtraction RIA method to measure the 79 
peptide, and the help of this method defined the peptide concentration in different tissues 80 
and proved the peptide presence in the circulation. [10]. Later confirmed, that the release 81 
of the thrittene is the effect of dining and get into the circulation. The components of the 82 
food affect the releasing of the peptides (somatostatin and thrittene). If the food is rich in 83 
carbohydrates, it increases the concentration of the thrittene in the plasma, while the food 84 
is rich in proteins that will affect the releasing of the somatostatin-28 [11]. From the fact 85 
that the thrittene and the somatostatin-28 respond differently to the components of the 86 
food, furthermore the histological distribution of this two peptide is diverse, concluded 87 
that the synthesis of the two peptides is not related, therefore the coding gene of the 88 
preprosomatostatin does not play a part in the biosynthesis of the thrittene [10, 11]. 89 
To confirm or confute the upper conclusion the research plane was designated to identify 90 
the somatostatin and thrittene concentrations in different rat brain areas with specific RIA 91 
methods, then define the somatostatin/thrittene ratio in every brain part. If this ratio 92 
shows huge variation (so the ratio if this two peptide producing cells is different in the 93 
investigated brain areas) we can confirm the conclusion. In that case the ratio is spreading 94 
around an average, and then we need to confute the previous researches. Because this 95 
could be possible in that case, when the somatostatin and the thrittene concentration 96 
parallel change in different brain parts, then the ratio remains constant. But in that case 97 
we need to suppose the thrittene is mostly produced during synthesis of the somatostatin 98 
(but we can not exclude totally different biosynthetic pathways).  99 
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In the presented research study we investigated the distribution of two biological active 100 
peptides in the rat nervous system with radioimmunoassay. This micro analytical 101 
technique is a competitive protein binding method for the quantitative determination of 102 
antigenically active substances that are present in very small amounts, such as peptide 103 
hormones. The concentration of an unknown, non-labelled antigen is determined by 104 
comparing its inhibitory effect on the binding of radioactively labelled antigen to a 105 
specific antibody with the inhibitory effects of known standards. The used direct specific 106 
thrittene RIA method was adjusted in 2012 in our laboratory [12]. But to measure the 107 
somatostatin we educed a new method. Our aim was to develop a method, which can 108 
measure at the same time both of the biologically active forms, somatostatin-28 and 14. 109 
The only way it was possible, if in the RIA used antibodies recognize and bind to the 110 
peptide’s common C-terminals. 111 
 112 
 113 
Table 1.  114 
Amino acid sequence of somatostatin, thrittene and cortistatin peptides. 115 
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 116 
Experimental 117 
Materials, drugs and chemicals 118 
 119 
Iodogen (1,3,4,6-tetrachloro-3,6-diphenil glycoluril), bovine serum albumin 120 
(BSA), sodium azide, glutardialdehyde, acetic acid, pentobarbitone sodium (Nembutal), 121 
incomplete Freund’s adjuvant, dialysis tubing and peptides (somatostatin-28, 122 
somatostatin-28 (1-14), somatostatin-28 (1-12), Tyr(0)-somatostatin-14, somatostatin-14 123 
(3-14)) were bought from Sigma (St. Louis, USA). Human cortistatin-17 and cortistatin-124 
29, rat cortistatin-14 and cortistatin-29 were obtained from Bachem (Bubendorf, 125 
Switzerland). Thrittene and Tyr(0)-thrittene were synthesized by G.K. Tóth (Department 126 
of Medical Chemistry, University of Szeged, Szeged, Hungary). Norit A (charcoal) and 127 
dextran FP 70 were purchased from Serva (Heidelberg, Germany); carrier-free Na125I, 128 
free from reducing agent for protein iodination from Institute of Isotopes (Budapest, 129 
Hungary); sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride 130 
and dichloromethane from VWR International (Debrecen, Hungary); trifluoroacetic acid 131 
(TFA) from Fluka (Buchs, Switzerland); HPLC-grade acetonitrile from Carlo Erba 132 
(Rodano, Italy). Polypropylene RIA tubes (12 x 75 mm) were obtained from Merck 133 
(Darmstadt, Germany). The animals (New Zeeland white rabbits and Wistar rats) were 134 
purchased from Charles River Laboratories (Budapest, Hungary).   135 
 136 
Description of thrittene radioimmunoassay 137 
 138 
 Thrittene RIA was performed in the study as previously described [12]. Briefly, 139 
the conditions were as follows: antisera of thrittene “TH3/6” was raised against a 140 
conjugate of thrittene and BSA coupled by glutaraldehyde in rabbit (dilution: 1:60000); 141 
tracer: mono-125I-labeled Tyr(0)-thrittene prepared in our laboratory (3000 cpm/tube); 142 
standard: synthetic thrittene ranging from 0 to 100 fmol/ml; buffer: assay prepared in 1 143 
ml of 0.05 mol/l (pH 7.4) phosphate buffer containing 0.1 mol/l sodium chloride, 0.25 % 144 
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(w/v) BSA and 0.05 % (w/v) sodium azide; incubation: 48 h at 4 °C; separation solution: 145 
charcoal/dextran/milk powder (10:1:0.2 g in 100 ml of distilled water); centrifugation: 146 
4000 rpm, 4 °C, 10 min.        147 
 148 
 149 
Development of somatostatin radioimmunoassay 150 
 151 
Synthesis of somatostatin-14        152 
 153 
Somatostatin-14: H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Phe-Thr-Ser-154 
Cys-OH (disulfide bridge: 3-14) was prepared applying tBoc chemistry. The peptide 155 
chain was elongated on a Pam resin (0.7 mmol/g) and the synthesis was carried out 156 
manually. The side-chain protecting groups were the followings: Boc-Lys(2ClZ),  Boc-157 
Cys(Meb) and Boc-Thr(Bzl). Couplings were performed with DCC and HOBt, without 158 
difficulties. Amino acid incorporations were monitored by quantitative ninhydrin test 159 
[13]. The completed peptide resin (1 g) was treated with liquid HF/dimethyl sulphide/p-160 
cresol/p-thiocresol (86:6:4:2 v/v), on 0 oC, 45 min. HF (hydrogen fluoride) was removed 161 
and the resulted free peptide was solubilized in 10 % aqueous acetic acid, filtered and 162 
lyophilized. The crude peptide (150 mg) was dissolved in distilled water (100 ml) and 3 163 
ml of 0.1 mmol/l potassium hexaciano ferrate (III) was added under stirring. After 3 164 
hours the solution was lyophilised and purified by semipreparative RP-HPLC using a 165 
solvent system of (A) 0.1 % TFA (trifluoroacetic acid) and (B) 80 % acetonitrile on a 166 
Phenomenex Jupiter (Torrance, California, USA) C18 10 μm column (15 x 250 mm). The 167 
HPLC apparatus was made by Knauer (Berlin, Germany). Absorbance was detected at 168 
220 nm. Purity of the cyclized peptide was evaluated by analytical RP-HPLC on a 4.6  169 
250 mm Phenomenex Luna C18 column using a HP 1100 HPLC system made by Hewlett 170 
Packard (Palo Alto, California, USA). The optimal HPLC conditions for the analytical 171 
controls were: flow: 1.0 ml/min; gradient: 35-50 % in 15 min.  172 
 173 
 174 
Preparation of BSA-somatostatin-14 immonogen        175 
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 176 
10 mg purified cyclized peptide (H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-177 
Phe-Thr-Ser-Cys-OH, disulfide bridge between the 3-14 Cys), 10 mg BSA and 16 µl 178 
glutardialdehyde were dissolved in 4 ml of phosphate buffer (pH 7.8) at 4 °C and was 179 
stirred for 12 hours. The incorporation of peptide into conjugate was monitored by 180 
addition of a trace amount (10000 cpm) of 125I-labelled RIA tracer to the reaction mixture 181 
[39]. Dialysis was made against distilled water using dialysis tubing at 4 °C for 48 h. The 182 
incorporation of label into conjugate was 73 %. The obtained conjugation mixture (BSA-183 
somatostatin-14 immunogen) was lyophilized and kept to be used for immunization. 184 
 185 
Immunization 186 
 187 
 Approximately 800 µg BSA-somatostatin-14 conjugate was emulsified in 1 ml of 188 
emulsion of Freund’s complete adjuvant and sterile saline (1:1) and injected 189 
intradermally, at 8-10 sites, into each of 5 young male New Zeeland white rabbits 190 
(weight: 2-2.2 kg). Further immunizations with the half of starting dose of conjugate (400 191 
µg/ml per animal) were made at 5-week intervals [39]. Finally, the rabbits were bled 192 
from an ear vein 2 weeks after the 5th, last successive immunizations. The collected sera 193 
were stored at –80 °C. The antisera were tested for titre and specificity by comparing the 194 
binding of several somatostain-like peptides in RIA conditions.   195 
 196 
Iodination of Tyr(0)-somatostatin-14 197 
 198 
 Freshly dissolved iodogen (10 g) in dichloromethane (100 l) was dispersed in 199 
the bottom of a polypropylene iodination vial and evaporated to dryness under nitrogen 200 
flow. Subsequently, 0.25 mol/l, pH 7.4 phosphate buffer (100 l) and Tyr(0)-somatostatin-201 
14 (20 nmol/40 l) were added together with 18.5 MBq/5 l carrier-free and free from 202 
reducing agent Na125I. The labeling process had been allowed to run for 4 min at room 203 
temperature. To terminate the iodogen mediated oxidizing reaction 0.1 % (v/v) TFA (400 204 
l) was administered into the reaction tube. Immediately thereafter, the reaction mixture 205 
was loaded onto a reversed-phase HPLC column for separation. 206 
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 207 
Reversed-phase HPLC separation 208 
 209 
 Radio-labeled products of the iodogen labeling reaction were fractionated by 210 
means of reversed-phase HPLC technique. The HPLC system comprised a Merck-Hitachi 211 
pump (type: L-7100), a Rheodyne injector (type: 7161), a LiChrospher 100 RP-18 (5 µm, 212 
4 x 250 mm) reversed-phase column and a Merck fraction collector (type: L-7650). The 213 
column was washed with acetonitrile (solvent B), then equilibrated with 0.1 % (v/v) TFA 214 
(solvent A) prior to use. HPLC-grade acetonitrile as an organic component along with 215 
aqueous solution of 0.1 % (v/v) TFA was employed to elute the radio-labeled peptides 216 
and free 125I- ion at a flow rate of 0.5 ml/min. Fractions at a volume of 0.5 ml were 217 
collected. Finally, the radioactivity of an aliquot volume (5 µl) of each fraction was 218 
determined in a gamma counter (Gamma NZ 310). 219 
Identification of various radioactive products 220 
 221 
Free iodine and mono- or di-iodinated forms of Tyr(0)-somatostatin-14 occurred as 222 
three distinct peaks after reversed-phase HPLC separation. Identification of the various 223 
products based on their order of appearance (free iodine occurring in the first peak) or 224 
binding to the raised somatostatin (SOM4/5) antibody (mono- or di-iodinated forms). 225 
Subsequently, determination of specific radioactivity of the radio-labeled peptides was 226 
performed by the self-displacement method described by Morris [14] to distinguish the 227 
mono-iodinated from the di-iodinated one. 228 
 229 
Description of somatostatin radioimmunoassay 230 
 231 
Antiserum: SOM4/5 was raised against a conjugate of somatostatin-14 and BSA 232 
coupled by glutaraldehyde in a rabbit.  233 
Tracer: mono-125I-labeled Tyr(0)-somatostatin-14 was prepared in our laboratory.  234 
Standard: somatostatin-14 was used as a RIA standard ranging from 0 to 200 235 
fmol/ml.  236 
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Buffer: the assay was prepared in 1 ml 0.05 mol/l (pH 7.4) phosphate buffer 237 
containing 0.1 mol/l sodium-chloride, 0.25 % (w/v) BSA and 0.05 % (w/v) sodium azide.  238 
Assay procedure: 100 l antiserum (working dilution 1:3000), 100 l RIA tracer 239 
(3,000 cpm/tube) and 100 l somatostatin-14 standard or unknown samples were 240 
measured into polypropylene tubes with the assay buffer. After 48 h incubation at 4 °C, 241 
the antibody-bound peptide was separated from the free one by addition of 100 l 242 
separating solution (10 g charcoal, 1 g dextran and 0.2 g commercial fat-free milk powder 243 
in 100 ml distilled water) [39]. Following centrifugation (4000 rpm, 4 °C, 10 min) the 244 
tubes were gently decanted and the radioactivity of the precipitates was measured in a 245 
gamma counter (Gamma NZ310). Somatostatin-14 concentrations of the unknown 246 
samples were read from a calibration curve. 247 
Every step of the RIA determination (preparation, incubation, separation) was carried out 248 
at low temperature, on ice or at 4 °C. The optimal incubation time for this somatostatin 249 
RIA is 48-72 hours at 4 °C (Fig. 1). 250 
 251 
 252 
Fig. 1. 253 
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The effect of incubation time on binding of somatostatin RIA tracer (mono-125I-labeled 254 
Tyr(0)-somatostatin-14) to SOM4/5 antibody at 4 °C. 255 
 256 
Animal tissue extraction  257 
   258 
Overnight fasting male Wistar rats (250-300 g) were anaesthetized with 50 mg/kg 259 
i.p. pentobarbitone sodium (Nembutal), killed by cervical dislocation and exsanguinated. 260 
Thereafter, the whole brain was removed and the following five brain areas were 261 
separated and collected: telencephalon, mesencephalon, cerebellum, hypothalamus and 262 
medulla oblongata. The tissue samples were placed on ice, after cooling, cleaned, 263 
weighed and homogenized in ice-cold distilled water to give a 10 % (w/v) homogenate. 264 
Finally the homogenates were centrifuged (10000 rpm, 4 °C, 30 min) and the 265 
supernatants were transferred for somatostatin and thrittene radioimmunoassay 266 
measurements. Content of peptides of various brain areas were expressed as fmol/mg wet 267 
tissue weight. Data are expressed as means ± standard error of means (SEM). 268 
 269 
Ethics 270 
 271 
The experimental protocols applied in the present work conformed to the 272 
European Community guiding principles for the care and use of laboratory animals and 273 
were approved by the Local Ethical Committee of the University of Debrecen, Hungary. 274 
 275 
Results  276 
Synthesis of somatostatin-14 277 
 278 
The lyophylisation of the pooled fractions led to 38.1 mg of pure somtostain-14, 279 
resulting 25.4 % overall yield. Analytical RP-HPLC: Phenomenex Luna (4.6 x 250 mm) 280 
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C18 column; flow: 1.0 ml/min; acetonitrile gradient: 35-50 % in 15 min; retention time: 281 
7.18 min; mass spectrometry: measured molecular weigh: 1637.4, calculated: 1637.89. 282 
(The synthetic peptide was characterized by mass spectrometry using a Finnigan TSQ 283 
7000 tandem quadrupol mass spectrometer equipped with electrospray ion source.) The 284 
pure peptide was used as RIA standard and for immunization in conjugated form. 285 
 286 
Reversed-phase HPLC separation of iodinated Tyr(0)-somatostatin-14 forms 287 
 288 
 On the basis of radioactivity measurements of the fractions collected, three 289 
distinct peaks occurred with respective retention times (Rt). The first one represented 290 
radioactivity of the free125I- ion (Rt: 5 min), the second peak (Rt: 27 min) showed 291 
radioactivity of the mono-iodinated form of Tyr(0)-somatostatin-14, whereas the third 292 
peak represented the di-iodinated form of Tyr(0)-somatostatin-14 (Rt: 32 min). Specific 293 
radioactivity values of mono- and di-iodinated peptides were 71.4 and 146.6 TBq/mmol. 294 
Radioactivity of the Tyr(0)-somatostatin-14 bound iodine accounted for approximately 84 295 
% (mono-iodinated 74 %, di-iodinated 10 %) of the total amount of activity consumed. 296 
Radioactivity of unincorporated 125I- ion (Rt: 5 min) was 6 %. The appropriate gradient of 297 
acetonitrile to separate mono- and di-iodinated forms of Tyr(0)-somatostatin-14 ranged 298 
from 25 to 27 % over 40 min (Fig. 2). 299 
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 300 
Fig. 2.  301 
Radiochromatogram of the Tyr(0)-somatostatin-14 forms separated by reversed-phase 302 
HPLC. The dashed line shows the acetonitrile gradient, the continuous line the 303 
radioactivity of fractions collected.  304 
 305 
Characterization of antiserums 306 
 307 
The raised somatostatin antiserums were tested for titre and specificity by 308 
comparing the binding of several somatostatin-like peptides. 309 
The titre values of the somatostatin antiserums were determined in assay conditions. The 310 
titre dilutions were as follows: SOM1/5 1:8000; SOM2/5 1:17000; SOM3/5 1:5000; 311 
SOM4/5 1:30000; SOM5/5 1:23000. Antiserum (SOM4/5) with the highest titre proved 312 
to be most successful for the development of RIA. This somatostatin antiserum, raised 313 
against a conjugate of BSA and somatostatin-14 turned to be C-terminal specific based 314 
on cross-reaction studies (Table 2).  315 
 316 
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Peptides             Cross-reactivity (%) 317 
Somatostatin-14      100.00 318 
Tyr(0)-somatostatin-14       95.54 319 
Somatostatin-14(3-14)       91.32 320 
Somatostatin-28        86.27 321 
Somatostatin-28(1-14)         0.00 322 
Somatostatin-28(1-12)         0.00 323 
Costistatin-14 (rat)       11.67 324 
Cortistatin-29 (rat)                    6.56 325 
Cortistatin-17 (human)         7.47 326 
Cortistatin-29 (human)         5.20 327 
Thrittene            0.00 328 
Tyr(0)-thrittene          0.00 329 
 330 
Table 2.  331 
Cross-reactivity data of the SOM4/5 somatostatin antiserum. The ID50 of somatostatin-332 
14 calibration curve served as a reference value. 333 
 334 
Somatostatin radioimmunassay characteristics 335 
 336 
The average ID50 value (i.e. the concentration of RIA standard (somatostatin-14), 337 
that displaces 50 % of the tracer from the antibody) was 15.18±2.02 fmol/ml as 338 
determined in ten consecutive assays (Fig. 3).  339 
 340 
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 341 
Fig. 3.  342 
Calibration curve of the somatostatin radioimmunoassay.  343 
Sensitivity  344 
Sensitivity of an assay is the minimum detectable concentration (detection limit) 345 
of the antigen. The detection limit of our somatostatin RIA was calculated from a 346 
decrease in binding of two standard deviations in the mean of zero standard of ten 347 
replicates [40]. This value was 0.24 fmol/ml. The lowest level of somatostatin-14 that can 348 
be detected by this assay is approximately 0.2 fmol/ml. 349 
Precission  350 
 Intra-assay precission (within assay variation) and inter-assay precission (between 351 
assay variation) was performed on three pooled samples containing varying 352 
concentrations (low, medium, high) of somatostatin-14. The measured concentrations of 353 
somatostatin-14 of the samples and the calculated data are presented in Table 3. Shown 354 
data are from ten duplicate determinations for within assay variation and ten consecutive 355 
duplicate determination for between assay variation.  356 
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  357 
Sample 
Intra-assay Inter-assay 
mean 
(fmol/ml) 
CV 
(%) 
mean 
(fmol/ml) 
CV 
(%) 
low 4.2 8.3 4.8 10.5 
medium 12.4 7.0 13.1 9.9 
high 20.4 6.5 19.3 8.3 
 358 
Table 3.  359 
Values of intra-assay and inter-assay coefficient of variation  360 
 361 
Somatostatin and thrittene contents of brain samples 362 
 363 
 Somatostatin immunoreactivity was present in the examined brain areas of rat 364 
with highest concentrations in the cerebellum followed by telencephalon, mesencephalon, 365 
hypothalamus and medulla oblongata. The thrittene immunoreactivity in the different 366 
brain parts showed a very similar tendency. The highest thrittene concentration was 367 
measured in the cerebellum, lowest in the medulla oblongata. The somatostatin 368 
concentration in every investigated tissue sample was approximately 5-fold higher than 369 
the determined thrittene content in the same brain area (Fig. 4). 370 
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 371 
Fig. 4.  372 
Distribution of somatostatin and thrittene in various rat brain areas measured by 373 
radioimmunoassay. Somatostatin and thrittene contents are expressed as fmol/mg wet 374 
tissue weight. Data are presented as means ± S.E.M. Abbreviations: SOM – somatostatin, 375 
THR – thrittene 376 
 377 
Discussion  378 
 379 
The present study provieded a descriptoin of a highly sensitive and specific 380 
radioimmunoassay method to measure a peptide called somatostatin in the radio-381 
analytical laboratory of our department. The objective of the present work was to develop 382 
a method, which can measure both of the biologically active forms of somatostatin 383 
(somatostatin-28 and 14) in the biological samples. The only way it was possible, if in the 384 
RIA used antibodies recognize and bind to the common C-terminals of the peptides. For 385 
this purpose glutaraldehyde coupling was used in this study to create the immunogen, due 386 
to the fact that this fixation method crosses the peptide through the N-terminal end to the 387 
carrier peptide (BSA). Consequently, the C-terminal part of the peptide remained free so 388 
the generated antibodies (mainly IgG) were produced against this sequence hence the 389 
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antibody recognizes the common C-terminal region of somatostatin-28 and 14. In the 390 
cross-reaction examination of our new “SOM4/5” antiserum we found a limited binding 391 
(5-10 %) to the rat and human cortistatin peptides (Table 1) but the values of these 392 
bindings are not important, so the antibody recognizes and binds mainly somatostatin-28 393 
and 14. 394 
125I is the most commonly used isotope for labeling of peptide hormones in order to 395 
perform RIA measurements. The widely applied oxidizing agents are: chloramine-T [15-396 
23, 40], hydrogen peroxide [24] and iodogen [12, 16, 25-31, 39]. After the labeling 397 
procedure the mono-iodinated Tyr(0)-somatostatin-14, serving later as RIA tracer, must be 398 
separated from the other compounds (di-iodinated Tyr(0)-somatostatin-14, unlabelled 399 
peptide, unincorporated iodine, oxidatively damaged labeled or unlabelled products). The 400 
present work provides a description of iodination, using iodogen, a solid-phase oxidizing 401 
agent, and separation by reversed-phase HPLC of Tyr(0)-somatostatin-14. High purity of 402 
the mono-125I-labelled Tyr(0)-somatostain-14, as a RIA tracer, is of crucial importance to 403 
carry out reliable measurements. Accordingly, the purpose of various iodination and 404 
separation procedures (gel filtration [16, 21, 23, 30, 32, 40], starch gel electrophoresis 405 
[33], paper electrophoresis [15, 20], thin layer chromatography [25, 28], ion-exchange 406 
chromatography [19, 34], reversed-phase HPLC [12, 15, 17, 22, 29, 31, 35-37, 39]) is to 407 
achieve the highest yield and purity of mono-iodinated form. Under optimal labeling and 408 
purification conditions as described above, the fraction of the mono-iodinated form can 409 
be as high as 70-75 %. The specific radioactivity values of the mono- and di-iodinated 410 
forms of Tyr(0)-somatostatin-14 are nearly identical with the theoretical values (78.63 and 411 
157.26 TBq/mmol) [38], documenting high efficacy of the reversed-phase HPLC 412 
separation technique employed. To prepare the optimal RIA tracer, the radioactive 413 
labeling must be as far as possible from the binding region. This problem was solved by 414 
coupling a Tyr amino acid, which is essential for the iodination, in zero position to the N-415 
terminal region of somatostatin-14. Incorporation of iodine into a peptide can modify the 416 
structure of the molecule, and if this modification is at the binding region, it can change 417 
the binding property or can extinguish it. In our case there was no such problem as the C-418 
terminal part is recognized by the antibody, the radioactive labeling was performed at the 419 
zero position of the N-terminal region. 420 
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As a practical application of the novel RIA, in this study the somatostatin concentration 421 
was measured parallel with the determination of thrittene content in different rat brain 422 
areas. The highest somatostatin concentrations were detected in the cerebellum followed 423 
by telencephalon, mesencephalon, hypothalamus and medulla oblongata. The thrittene 424 
immunoreactivity in the same brain parts showed a similar tendency. It is striking that in 425 
all cases the ratio of the two peptides are almost the same, namely the amount of the 426 
somatostatin measured in the same samples is about 5 times the thrittene concentration. 427 
(Our work group has found similar results in a previous project, when comparing the 428 
somatostatin and thrittene concentration of specific intestinal regions.) These results 429 
verify our following theory: thrittene is not created via a specific biosynthetical route, but 430 
from the pre-prosomatostatin, and is one of its split products. If it was created in a 431 
different way, then in our opinion at least in some organs the ratio of the two peptides 432 
would be different. In our future experiments concerning digesting we will try to exactly 433 
prove (or peremptorily rule out) that thrittene is the degradation product of the S-28. 434 
According to our hypothesis the peptide is made when the 28-amino acid somatostatin 435 
splits, and from the C terminal region the S-14 forms (also with full biological activity). 436 
The remaining N terminal region contains the structure of the thrittene, however, one 437 
additional amino acid (Lys) has to be split off beforehand. During the experiment we will 438 
incubate native somatostatin-28 at 37°C in homogenisation of different organs for 439 
different amounts of time, giving the peptidase enzymes opportunity to split the S-28, and 440 
the peptides created during this process. After this, as the first step, using specific RIA 441 
methods, we will measure the thrittene and somatostatin concentrations of the organ 442 
media. If the thrittene amount in the incubated samples exceeds the basic amount, or if 443 
this shows a growing tendency during the incubation time, this will be an evidence for the 444 
biosynthesis of the thrittene. Of course, the peptides created during the incubation will be 445 
analyzed and identified. Methods for these may be HPLC separation and then amino acid 446 
analysis. 447 
 448 
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